Planning for Market Sustainability Under New Policy Frameworks

EP: 1.Current Perspective on Pricing and Reimbursement Models

EP: 2.Overcoming Regulatory Barriers to Market Access

EP: 3.Delivering Value Beyond the Trial with Real-World Evidence

EP: 4.Aligning Real-World Evidence with Payer Perspectives

EP: 5.Navigating Market Entry Challenges for Orphan Drugs

EP: 6.Effective Tactics for Pricing and Reimbursement in Today’s Market

EP: 7.Designing Effective Value-Based Contracts: Timing, Evidence, and Risk Alignment

Now Viewing

EP: 8.Planning for Market Sustainability Under New Policy Frameworks

The Most Favored Nation (MFN) pricing policy aims to align US drug prices with lower international rates. The panelists share varying perspectives on this policy, including its uncertain future, the need for greater pricing transparency, and how manufacturers might defend price differences based on value, clinical investment, and regulatory requirements. Also discussed are potential overlaps with the Inflation Reduction Act and the crucial role that proactive advocacy plays in a changing policy landscape.

Key discussion topics include:

• The potential impact of MFN pricing on US drug costs and the current market.
• Why pricing transparency and value justification are increasingly essential for pharmaceutical companies.
• The role of scenario planning and value proposition refinement in navigating regulatory uncertainty.